![Patrick Michael Round](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Patrick Michael Round
Chief Tech/Sci/R&D Officer at
NewAmsterdam Pharma BV
Profile
Patrick Michael Round is the founder of ario pharma Ltd. He currently holds three positions, including Director at Xention Ltd., Venture Partner at Forbion Capital Partners Management Holding BV, and Chief Medical Officer at NewAmsterdam Pharma BV.
Previously, he held positions such as Director of Clinical Development at Glaxo Wellcome Plc, Development Director at Celltech R&D, Inc., Senior Vice President at MedImmune Ltd., Principal at Novo Nordisk A, and Chief Medical Officer at Xention Pharma Ltd. He also served as Principal at the Faculty of Pharmaceutical Medicine.
Dr. Round received his undergraduate degree from the University of London in 1982.
Patrick Michael Round active positions
| Companies | Position | Start |
|---|---|---|
NewAmsterdam Pharma BV
 NewAmsterdam Pharma BV Pharmaceuticals: MajorHealth Technology Develops novel drugs to treat dyslipidemia | Chief Tech/Sci/R&D Officer | - |
Xention Ltd.
 Xention Ltd. Pharmaceuticals: MajorHealth Technology Develops and researches drugs | Director/Board Member | 2016-05-16 |
Forbion Capital Partners Management Holding BV
 Forbion Capital Partners Management Holding BV Investment ManagersFinance Forbion is an active manager invest companies located in Northwest Europe and the United States. The firm focuses on companies operating in the fields of life sciences and biomedical technology. It participates in early stage capital requirements with an investment size ranging from EUR 1 - 7 million. It participates in follow-on investments, takes a board seat and acts as lead investor. | Private Equity Investor | 2017-12-31 |
Former positions of Patrick Michael Round
| Companies | Position | End |
|---|---|---|
ario pharma Ltd.
 ario pharma Ltd. Pharmaceuticals: MajorHealth Technology Develops drugs for the treatment of respiratory indications | Founder | - |
Glaxo Wellcome Plc
 Glaxo Wellcome Plc Pharmaceuticals: MajorHealth Technology Researches, develops, manufactures and markets pharmaceuticals | Chief Tech/Sci/R&D Officer | 2011-06-27 |
Celltech R&D, Inc.
 Celltech R&D, Inc. Drugstore ChainsRetail Trade Provides research and development for pharmaceutical products | Corporate Officer/Principal | - |
Xention Pharma Ltd.
 Xention Pharma Ltd. Pharmaceuticals: MajorHealth Technology Develops and researches drugs | Chief Tech/Sci/R&D Officer | - |
Faculty of Pharmaceutical Medicine | Corporate Officer/Principal | - |
Training of Patrick Michael Round
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Connections
89
1st degree connections
11
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 11 |
|---|---|
Glaxo Wellcome Plc
Glaxo Wellcome Plc Pharmaceuticals: MajorHealth Technology Researches, develops, manufactures and markets pharmaceuticals | Health Technology |
MedImmune Ltd.
 MedImmune Ltd. BiotechnologyHealth Technology Engages in research and development of human monoclonal antibodies | Health Technology |
Novo Nordisk A/S
 Novo Nordisk A/S Pharmaceuticals: MajorHealth Technology Manufactures and markets pharmaceutical products for diabetes care | Health Technology |
Xention Pharma Ltd.
Xention Pharma Ltd. Pharmaceuticals: MajorHealth Technology Develops and researches drugs | Health Technology |
University of London
 University of London Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Forbion Capital Partners Management Holding BV
Forbion Capital Partners Management Holding BV Investment ManagersFinance Forbion is an active manager invest companies located in Northwest Europe and the United States. The firm focuses on companies operating in the fields of life sciences and biomedical technology. It participates in early stage capital requirements with an investment size ranging from EUR 1 - 7 million. It participates in follow-on investments, takes a board seat and acts as lead investor. | Finance |
Faculty of Pharmaceutical Medicine | |
Celltech R&D, Inc.
Celltech R&D, Inc. Drugstore ChainsRetail Trade Provides research and development for pharmaceutical products | Retail Trade |
ario pharma Ltd.
ario pharma Ltd. Pharmaceuticals: MajorHealth Technology Develops drugs for the treatment of respiratory indications | Health Technology |
Xention Ltd.
Xention Ltd. Pharmaceuticals: MajorHealth Technology Develops and researches drugs | Health Technology |
NewAmsterdam Pharma BV
NewAmsterdam Pharma BV Pharmaceuticals: MajorHealth Technology Develops novel drugs to treat dyslipidemia | Health Technology |
- Stock Market
- Insiders
- Patrick Michael Round
